














Key figures

Roche Group

Index 2005 = 100



Price development of non-voting equity security (*Genussschein*) in CHF



1) Key figures indexed to 2005 = 100.

2) Proposed by the Board of Directors.

3) Development phase I to IV.

4) For calculation of the Eco-Efficiency Rate see:
www.roche.com/sus-she_performance

Figures for 2005 as in Annual Report 2006.

For a full index of Global Reporting Initiative (GRI) indicators used in the report see: www.roche.com/sus-gri

The year 2007 in brief

Roche Group

- Group sales grow 10% to 46.1 billion Swiss francs.
- Operating profit up by 22% to 14.5 billion Swiss francs.
- Increase in net income of 25% in Swiss francs to 11.4 billion Swiss francs.
- Increase in Core EPS¹⁾ of 20% in Swiss francs to 11.85 Swiss francs.
- Increase in proposed dividend of 35% from 3.40 to 4.60 Swiss francs, representing the 21st consecutive year of dividend growth.

Pharmaceuticals

- Division posts double-digit sales growth of 11% (13% excluding Tamiflu pandemic sales) to 36.8 billion Swiss francs again significantly outpacing global markets.
- Operating profit up by 22% to 13.0 billion Swiss francs and operating profit margin up by 3.8 percentage points to 35.5%.
- Additional indications and introductions strengthen leadership position in oncology.
- Mircera launched in Europe for treatment of renal anemia.
- Actemra filed in US and EU for rheumatoid arthritis.
- Substantially higher R&D expenses of 7.6 billion Swiss francs reflect strong pipeline and large number of late-stage clinical trials.
- New agreements with Transgene (therapeutic vaccines), Toyama (rheumatoid arthritis) and Alnylam (RNAi).

Diagnostics

- Division maintains global market leadership as sales rise 6% to 9.3 billion Swiss francs.
- Operating profit increases to 1.6 billion Swiss francs, and operating profit margin up 1.3 percentage points to 17.6%.
- Acquisitions of 454 Life Sciences, BioVeris Corporation and NimbleGen Systems, Inc. completed.
- Merger agreement signed with Ventana Medical Systems, Inc. (US).

Outlook

- High single-digit sales increase for the Group²⁾.
- Sales increase of both Divisions²⁾ above market growth.
- Core Earnings per Share³⁾ target at least at record 2007 level despite significant increase in R&D investment and considerably lower Tamiflu pandemic sales.
- Continued increase in dividend payout ratio over next three years.

For additional information about Roche, visit <http://www.roche.com>

Barring unforeseen events

Unless otherwise stated, all growth rates are in local currencies.

1) Core EPS (Earnings per Share).

2) Excluding Tamiflu pandemic sales.

3) Core Earnings per Share target is based on constant exchange rates.